Skip to main content
Only direct cytotoxic targets are shown
Gene
Drug Category
Drug Class
Download CSV
Gene NCT ID Antigen/Ligand Binding Type Drug Name Drug NCI Concept Drug Category Drug Class Drug Description Drug Mechanism of Action Target Cytotoxicity Mechanism Disease Disease Type Tissue OncoTree Main Type OncoTree Name Annotation Status
EGFR NCT06670196 EGFR other Osimertinib C116377 SMALL MOLECULE DRUG Inhibitor Third‑generation, irreversible small‑molecule EGFR tyrosine kinase inhibitor that targets mutant EGFR (exon 19 deletion/L858R ± T790M), suppressing downstream MAPK and PI3K/AKT signaling. Third‑generation, irreversible, mutant‑selective EGFR tyrosine kinase inhibitor that covalently inhibits mutant EGFR (exon 19 deletion, L858R, and T790M), blocking downstream MAPK and PI3K/AKT signaling to suppress tumor growth and induce cancer cell death. Osimertinib covalently inhibits mutant EGFR kinase (e.g., exon 19 deletion, L858R, T790M), blocking MAPK and PI3K/AKT survival signaling and inducing apoptosis of EGFR‑mutant tumor cells. Non-Small Cell Lung Cancer CANCER Lung Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer ai
UNKNOWN NCT05971589 Patient-specific tumor neoantigen peptide presented by HLA class I (peptide–MHC-I) antigen recognition LM103 C187659 TUMOR INFILTRATING LYMPHOCYTES Unedited cells Autologous tumor-infiltrating lymphocyte (TIL) adoptive cell therapy composed of ex vivo–expanded patient CD8+/CD4+ TILs reinfused to mediate TCR-dependent recognition and cytotoxic killing of tumor antigen–bearing cells. Autologous, ex vivo–expanded CD8+/CD4+ tumor-infiltrating T lymphocytes are reinfused to recognize tumor antigen–bearing cells via native TCRs and mediate cytotoxic killing (e.g., perforin/granzyme), leading to antitumor immune responses; product is non–genetically engineered and activity is typically supported by lymphodepletion and IL-2. Reinfused TILs recognize the neoantigen peptide–MHC-I via native TCRs and directly kill target cells through cytotoxic T-cell mechanisms (perforin/granzyme-mediated apoptosis, Fas–FasL). Solid Tumor CANCER Other Solid Tumors Solid Tumors manual_review_required
UNKNOWN NCT05971589 Shared/non-mutated tumor-associated antigen peptide presented by HLA class I (peptide–MHC-I) antigen recognition LM103 C187659 TUMOR INFILTRATING LYMPHOCYTES Unedited cells Autologous tumor-infiltrating lymphocyte (TIL) adoptive cell therapy composed of ex vivo–expanded patient CD8+/CD4+ TILs reinfused to mediate TCR-dependent recognition and cytotoxic killing of tumor antigen–bearing cells. Autologous, ex vivo–expanded CD8+/CD4+ tumor-infiltrating T lymphocytes are reinfused to recognize tumor antigen–bearing cells via native TCRs and mediate cytotoxic killing (e.g., perforin/granzyme), leading to antitumor immune responses; product is non–genetically engineered and activity is typically supported by lymphodepletion and IL-2. Autologous TILs recognize the shared tumor-associated antigen peptide presented on HLA class I via native TCRs and directly kill the presenting cells through perforin/granzyme cytolysis (and Fas–FasL apoptosis). Solid Tumor CANCER Other Solid Tumors Solid Tumors manual_review_required
UNKNOWN NCT05971589 Patient-specific tumor neoantigen peptide presented by HLA class II (peptide–MHC-II) antigen recognition LM103 C187659 TUMOR INFILTRATING LYMPHOCYTES Unedited cells Autologous tumor-infiltrating lymphocyte (TIL) adoptive cell therapy composed of ex vivo–expanded patient CD8+/CD4+ TILs reinfused to mediate TCR-dependent recognition and cytotoxic killing of tumor antigen–bearing cells. Autologous, ex vivo–expanded CD8+/CD4+ tumor-infiltrating T lymphocytes are reinfused to recognize tumor antigen–bearing cells via native TCRs and mediate cytotoxic killing (e.g., perforin/granzyme), leading to antitumor immune responses; product is non–genetically engineered and activity is typically supported by lymphodepletion and IL-2. Reinfused TILs use native TCRs to recognize the neoantigen peptide–HLA class II complex and directly kill target cells via perforin/granzyme-mediated apoptosis (and Fas–FasL). Solid Tumor CANCER Other Solid Tumors Solid Tumors manual_review_required
UNKNOWN NCT05971589 Shared/non-mutated tumor-associated antigen peptide presented by HLA class II (peptide–MHC-II) antigen recognition LM103 C187659 TUMOR INFILTRATING LYMPHOCYTES Unedited cells Autologous tumor-infiltrating lymphocyte (TIL) adoptive cell therapy composed of ex vivo–expanded patient CD8+/CD4+ TILs reinfused to mediate TCR-dependent recognition and cytotoxic killing of tumor antigen–bearing cells. Autologous, ex vivo–expanded CD8+/CD4+ tumor-infiltrating T lymphocytes are reinfused to recognize tumor antigen–bearing cells via native TCRs and mediate cytotoxic killing (e.g., perforin/granzyme), leading to antitumor immune responses; product is non–genetically engineered and activity is typically supported by lymphodepletion and IL-2. TILs recognize the peptide–HLA class II complex via native CD4+ TCRs and directly kill target cells through perforin/granzyme (and Fas–FasL) cytotoxic pathways. Solid Tumor CANCER Other Solid Tumors Solid Tumors manual_review_required
Displaying 2451 - 2455 of 3741